List of Excipients in Branded Drug TRIPLE ANTIBIOTIC HC

Generic Drugs Containing TRIPLE ANTIBIOTIC HC

Company	Ingredient	NDC	Excipient
Phoenix Pharmaceutical Inc	neomycin sulfate and polymyxin b sulfate, bacitracin zinc and hydrocortisone	57319-344	MINERAL OIL
Phoenix Pharmaceutical Inc	neomycin sulfate and polymyxin b sulfate, bacitracin zinc and hydrocortisone	57319-344	PETROLATUM

What are the Most Frequently-Used Excipients in TRIPLE ANTIBIOTIC HC?

# Of NDCs	Excipient
1	MINERAL OIL
1	PETROLATUM

Last updated: September 16, 2026

Executive summary: Triple Antibiotic HC is a topical combination of bacitracin, neomycin, polymyxin B, and hydrocortisone. Its commercial value is driven by formulation performance, tolerability, packaging, and channel access rather than active-ingredient exclusivity. A petroleum ointment with controlled drug uniformity, low microbial risk, clean application, and differentiated packaging offers the strongest near-term opportunity. U.S. market entry is likely to depend on the applicable FDA regulatory pathway, product-specific labeling, and demonstration of pharmaceutical equivalence rather than new chemical-entity patents.

Triple Antibiotic HC Excipient Strategy and Commercial Opportunities

What is Triple Antibiotic HC?

Triple Antibiotic HC is a topical anti-infective and corticosteroid combination generally associated with:

Component	Typical function
Bacitracin zinc	Topical antibacterial
Neomycin sulfate	Topical aminoglycoside antibacterial
Polymyxin B sulfate	Topical antibacterial
Hydrocortisone	Low-potency corticosteroid used to reduce inflammation and itching
Ointment base	Drug delivery, skin coverage, moisture retention, and product stability

U.S. labeling for products containing this combination generally identifies the product as a topical ointment for limited skin conditions where bacterial infection and inflammatory symptoms occur. The product is not interchangeable with ordinary triple-antibiotic ointment because hydrocortisone changes the labeling, risk profile, regulatory classification, and clinical positioning.[1]

Triple Antibiotic HC should be analyzed as a mature topical combination product. The active ingredients have long histories of use, so commercial differentiation depends on:

• Excipient selection
• Microbiological quality
• Drug distribution throughout the ointment
• Ease of spreading and removal
• Tube and closure design
• Preservative strategy
• Pediatric and sensitive-skin positioning
• Retail, institutional, and private-label distribution

What excipients are most suitable for Triple Antibiotic HC?

The strongest baseline excipient system is an anhydrous hydrocarbon ointment based on white petrolatum, with mineral oil or a comparable liquid hydrocarbon used to adjust consistency.

Recommended baseline formulation architecture

Formulation function	Preferred excipient approach	Commercial rationale
Primary ointment base	White petrolatum	Occlusive, low-cost, chemically stable, widely accepted in topical products
Consistency adjustment	Mineral oil or light liquid paraffin	Improves spreadability and controls firmness
Drug wetting	Mineral oil or compatible hydrocarbon phase	Helps disperse powders and reduce grittiness
Antioxidant protection	Usually unnecessary for a simple hydrocarbon base; evaluate if oxidation-sensitive materials are introduced	Avoids unnecessary excipient complexity
Preservative	Prefer preservative-free design if water activity remains negligible	Reduces sensitization and compatibility risks
Chelation	Generally unnecessary unless justified by stability data	Avoids added regulatory and dermatologic burden
Humectant	Usually avoided in anhydrous ointments	May increase water activity and microbial-control requirements
Emulsifier	Not required for a true hydrocarbon ointment	Avoids phase instability and unnecessary ingredients
Fragrance and color	Exclude	Reduces irritation, allergy, and consumer-perception risk

A petrolatum-mineral oil system is commercially attractive because it has a long regulatory history and minimizes the number of excipients that must be justified. It also supports anhydrous manufacturing, which reduces microbial growth risk and simplifies preservation.

Why anhydrous excipients are strategically important

The active ingredients are salts or powders with different physical properties. Bacitracin zinc, neomycin sulfate, and polymyxin B sulfate must be uniformly distributed in a semisolid base. A water-containing cream or gel can improve cosmetic feel, but it introduces additional technical requirements:

• Preservative efficacy
• Emulsion stability
• Microbial limits
• pH control
• Water-loss control
• Compatibility among sulfate salts and the vehicle
• Greater risk of phase separation during storage

An anhydrous ointment avoids many of these problems. Its principal disadvantages are greasiness, slower absorption, and less favorable cosmetic acceptance. Those disadvantages create an opportunity for a differentiated cream or emulgel, but the development and regulatory burden is higher.

What formulation attributes create commercial value?

The highest-value attributes are uniformity, skin feel, low irritation potential, and packaging performance.

Drug uniformity

The four active ingredients have different concentrations, particle properties, and density. Poor blending can create potency variability between samples, especially in small-volume tubes. Development should focus on:

1. Particle-size control for each active.
2. Controlled order of addition.
3. Geometric dilution for low-dose ingredients.
4. Vacuum or low-shear mixing to limit air entrapment.
5. In-process sampling from multiple locations.
6. Homogeneity testing for each active ingredient.

A manufacturer that can demonstrate tighter content uniformity than competing products may obtain an operational advantage in quality audits, institutional procurement, and regulatory review.

Spreadability and residue

White petrolatum provides strong occlusion but can feel heavy. Mineral oil can lower viscosity and improve spreading, but excessive levels may cause leakage, migration, or reduced residence time.

A commercially balanced formulation should target:

• Smooth application without visible particles
• Minimal drag during spreading
• No oil separation
• No excessive tack
• Adequate retention on the affected area
• Removal with ordinary cleansing products
• Acceptable performance under warm-storage conditions

These attributes can support product differentiation even when the active ingredients are not patent-protected.

Irritation and sensitization control

Neomycin is a recognized cause of allergic contact dermatitis. Bacitracin can also cause sensitization. Hydrocortisone may reduce inflammatory symptoms but does not eliminate the risk of allergic reactions to the antibiotics.

Excipient strategy should therefore exclude avoidable sensitizers. Fragrance, essential oils, lanolin, formaldehyde-releasing preservatives, and unnecessary botanical materials create limited commercial upside and can increase dermatologic risk. A short, familiar inactive-ingredient list is more suitable for pediatric, dermatology, and institutional channels.

What formulations are protected by patents?

The active-ingredient combination is mature, and broad composition-of-matter patent protection is not expected to provide a meaningful barrier for a modern generic or private-label entrant. Potentially protectable subject matter is more likely to involve:

• A specific concentration range
• A defined particle-size distribution
• A low-irritation ointment base
• A waterless cream or emulgel
• Improved drug uniformity
• A manufacturing sequence
• A single-dose or unit-dose delivery system
• A tamper-evident package
• A formulation with improved washability
• A stability profile under accelerated conditions

A formulation patent must provide more than a conventional mixture of petrolatum, mineral oil, and known antibiotic salts. The strongest claim strategy would connect a defined excipient ratio or manufacturing parameter to a measurable technical result, such as reduced phase separation, improved content uniformity, or extended stability.

Patent applicants should avoid relying solely on broad claims covering “an ointment comprising bacitracin, neomycin, polymyxin B, and hydrocortisone.” Such claims face substantial validity risk because the combination and common ointment vehicles have long prior-art histories.

When does Triple Antibiotic HC lose exclusivity?

Triple Antibiotic HC does not have the exclusivity profile of a new molecular entity. The principal commercial barriers are regulatory approval, manufacturing capability, product quality, and distribution rather than a long-lived active-ingredient patent.

The relevant U.S. exclusivity categories are:

Exclusivity type	Relevance to Triple Antibiotic HC
New chemical entity exclusivity	Not applicable to the mature active ingredients
Five-year NCE exclusivity	Not applicable
Three-year clinical-investigation exclusivity	Possible only if a qualifying approval relied on new clinical investigations
Orphan-drug exclusivity	Not applicable to the conventional indication
Pediatric exclusivity	Possible only if separately granted
Patent exclusivity	Product-specific and dependent on Orange Book-listed patents
ANDA market exclusivity	Possible for a first qualifying generic applicant with a Paragraph IV challenge

The product should therefore be evaluated through the relevant FDA approval record, Orange Book listing, labeling history, and any listed patents. FDA’s Orange Book identifies approved drug products and, where applicable, patents and exclusivity periods.[2]

What is the Orange Book status of Triple Antibiotic HC?

The Orange Book status depends on the exact sponsor, dosage form, strength, and application number. “Triple Antibiotic HC” is not sufficient by itself to establish a single Orange Book record because similar products may be marketed under different sponsors, labels, and abbreviated new drug applications.

For commercial diligence, the key records are:

• FDA application number
• Reference listed drug, if applicable
• Strength of each active ingredient
• Ointment or cream dosage form
• Listed patents
• Pediatric exclusivity
• Approval status
• Therapeutic-equivalence code
• Discontinued or active marketing status

A generic entrant must establish pharmaceutical equivalence and bioequivalence, or otherwise satisfy the applicable approval standard for the product category. For a topical semisolid, FDA may evaluate comparative formulation attributes, product quality, and performance through the applicable ANDA pathway and product-specific guidance.[3]

Are Paragraph IV challenges relevant?

Paragraph IV risk is relevant if a branded or reference product has unexpired patents listed in the Orange Book. A generic applicant may certify that listed patents are invalid, unenforceable, or will not be infringed. A Paragraph IV notice can trigger patent litigation and a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory conditions.[4]

For Triple Antibiotic HC, Paragraph IV exposure is likely to be more important for:

• A branded formulation with a patented vehicle
• A cream or gel with novel delivery properties
• A product supported by newer clinical or performance data
• A package or dosing system covered by listed claims

A conventional petrolatum ointment containing the established active combination generally presents a weaker basis for durable patent blocking than a novel topical delivery system.

What patent litigation affects Triple Antibiotic HC?

No broad, product-specific litigation conclusion should be drawn from the product name alone. Litigation analysis must be tied to a particular reference listed drug, FDA application, sponsor, and patent number.

The principal litigation theories would include:

• Infringement of formulation claims
• Infringement of manufacturing-process claims
• Invalidity based on anticipation or obviousness
• Noninfringement based on different excipient ratios
• Failure to meet claim limitations involving particle size or water content
• Regulatory exclusivity disputes
• Labeling disputes involving hydrocortisone indications

Because the active ingredients are old, litigation strength is more likely to depend on narrow technical claims than on broad combination claims.

What are the strongest commercial opportunities?

1. Private-label pharmacy and mass retail

A compliant, low-cost ointment can compete through retailer brands, pharmacy chains, and regional distributors. The main requirements are reliable supply, stable tube filling, low complaint rates, and a simple inactive-ingredient profile.

2. Dermatology and wound-care channels

A product positioned around controlled application, low residue, and sensitive-skin tolerability may have value in dermatology and outpatient wound-care settings. Promotional claims must remain within the approved labeling.

3. Unit-dose packaging

Single-use sachets or small foil packets may support hospitals, urgent-care clinics, first-aid kits, and travel products. Unit-dose packaging can reduce cross-contamination and improve inventory control. It also creates potential patent and trade-secret opportunities around filling, sealing, and package compatibility.

4. Improved cosmetic formulations

A cream or emulgel with lower greasiness could target consumers who reject petrolatum ointments. The opportunity is technically more difficult because the product would need robust preservation, stability, and drug-distribution data.

5. Preservative-free positioning

Anhydrous packaging supports a preservative-free product. This may appeal to pediatric and sensitive-skin segments, although the claim must be supported by formulation and microbiological data.

6. Regional licensing and contract manufacturing

The product is suitable for licensing where a local pharmaceutical company has:

• A validated topical manufacturing line
• Tube-filling capacity
• Existing antibiotic distribution
• Regulatory experience with combination products
• Hospital or pharmacy contracts

A licensing agreement would likely create more value through manufacturing scale and distribution rights than through patent royalties.

How does Triple Antibiotic HC compare with competing topical products?

Product category	Antibacterial coverage	Steroid component	Main commercial advantage	Main limitation
Triple Antibiotic HC	Broad topical combination	Hydrocortisone	Addresses infection and inflammation in one product	Sensitization and steroid-label restrictions
Triple antibiotic ointment	Broad topical combination	None	Familiar, inexpensive, widely distributed	Does not address inflammatory symptoms
Hydrocortisone ointment	None	Hydrocortisone	Anti-inflammatory positioning	Does not treat bacterial infection
Mupirocin ointment	Targeted antibacterial	None	Prescription clinical positioning	Different spectrum and prescription access
Retapamulin ointment	Targeted antibacterial	None	Alternative prescription option	Narrower commercial footprint
Antifungal-steroid combination	Antifungal plus steroid	Varies	Targets fungal-inflammatory conditions	Not a substitute for bacterial indications

The combination has commercial logic when both bacterial contamination or infection and inflammation are present. It is less attractive for routine minor wounds where a nonsteroidal antibiotic product may have simpler labeling and lower steroid-related risk.

What manufacturing and intellectual-property barriers exist?

The major manufacturing barrier is achieving reproducible dispersion of all active ingredients in a semisolid base. Key controls include:

• Raw-material particle size
• Active potency and moisture
• Blend uniformity
• Mixing temperature
• Shear exposure
• Filling temperature
• Tube compatibility
• Long-term and accelerated stability
• Microbial limits
• Net-content control

The most defensible proprietary position would likely be a manufacturing process, specialized package, or technically differentiated vehicle. Trade-secret protection may be more practical than patent protection for mixing order, processing temperature, and scale-up parameters.

Geographic coverage should be planned separately. U.S. approval does not establish authorization in the European Union, Canada, Japan, or emerging markets. Each jurisdiction may classify the product differently as a medicinal product, OTC medicine, prescription product, or combination requiring additional data. FDA’s labeling and monograph framework cannot be transferred directly to other markets.[5]

What is the revenue exposure and generic-launch risk?

Public revenue data for Triple Antibiotic HC are not generally reported as a standalone segment. Revenue exposure must therefore be estimated using:

• Unit volume
• Average selling price
• Channel mix
• Tube size
• Reimbursement status
• Retail versus institutional sales
• Number of approved competitors
• Supply reliability
• Private-label penetration

Generic-launch risk is high for a conventional formulation because the ingredients are mature and the technical concept is readily understood. Risk is lower where the incumbent has:

• A patented vehicle
• A strong hospital contract base
• Superior tube performance
• A differentiated cream or gel
• Reliable supply during competitor shortages
• Brand recognition in a narrow specialty channel

A new entrant should prioritize formulation quality and distribution economics over an expensive broad patent program.

Key Takeaways

• Triple Antibiotic HC is a mature topical combination of bacitracin, neomycin, polymyxin B, and hydrocortisone.
• A preservative-free, anhydrous petrolatum-mineral oil ointment is the lowest-risk formulation platform.
• The strongest commercial differentiators are spreadability, low residue, uniform drug distribution, packaging, and supply reliability.
• Broad active-ingredient patent protection is unlikely to create a durable barrier.
• Formulation, manufacturing-process, and unit-dose packaging patents offer more credible protection.
• Orange Book and Paragraph IV analysis must be conducted against a specific FDA application and reference listed drug.
• Private-label retail, institutional supply, unit-dose packaging, and cosmetically improved formulations are the clearest commercial opportunities.
• Generic-launch risk is high for a conventional ointment and lower for a technically differentiated delivery system.

FAQs

Is Triple Antibiotic HC the same as ordinary triple-antibiotic ointment?

No. Triple Antibiotic HC includes hydrocortisone, while ordinary triple-antibiotic ointment generally contains the three antibacterials without a corticosteroid.

Can Triple Antibiotic HC be formulated without preservatives?

Yes, an anhydrous hydrocarbon ointment can generally be designed without a conventional preservative, subject to stability, microbial-limit, packaging, and regulatory testing.

Does hydrocortisone create a separate patent opportunity?

Hydrocortisone itself is old. Commercial protection would need to come from a specific formulation, delivery system, manufacturing process, or package rather than from hydrocortisone alone.

Is a cream commercially better than an ointment?

A cream may provide better cosmetic acceptance and washability, but it creates greater technical requirements for preservation, emulsion stability, and active uniformity.

What is the most defensible IP strategy for a new Triple Antibiotic HC product?

A focused strategy combining narrow formulation claims, process know-how, package protection, trade secrets, and regulatory execution is more credible than broad claims covering the established active combination.

References

1. DailyMed. (n.d.). Neomycin sulfate, polymyxin B sulfate, bacitracin zinc, and hydrocortisone topical ointment labeling. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2022). Product-specific guidance for generic drug development. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and the Paragraph IV certification process. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21: Topical drug products and labeling requirements. U.S. Department of Health and Human Services.